← SEC 公告列表 | AAPG SEC 公告 | 亚盛医药（AAPG）

重大事件 外國發行人報告 6-K 2026-07-13

亞盛醫藥提交6-K 更正股東大會日期 釐清股權激勵授權限額

於 SEC 網站開啟原文

AI 繁中摘要

亞盛醫藥集團（Ascentage Pharma Group International，股份代號：6855）於2026年7月13日提交6-K表格，更新2021年及2022年受限制股份單位（RSU）計劃，以及上市後購股權計劃的進一步授予詳情。 是次公告為2026年6月29日發佈的公告之補充，主要澄清一項日期錯誤：原公告中提及的年度股東大會日期應為2025年5月19日（而非2026年5月20日），該日期為釐定2021年、2022年獎勵及購股權計劃授權限額之基準。除此項修正外，原有公告其他內容維持不變。 對投資者而言，此修訂僅屬技術性更正，不影響股權激勵計劃的實際授予條款或公司財務狀況。投資者應留意，亞盛醫藥持續透過股權激勵計劃吸引及留住人才，相關計劃授權限額已於2025年股東大會獲批，反映公司治理合規性。
展開英文正文 
EX-99.1
2
ea029788201ex99-1.htm
ANNOUNCEMENT DATED JULY 13, 2026

 

Exhibit
99.1

 

Hong
Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.

 

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman
Islands with limited liability)

(Stock Code: 6855)

 

UPDATE ON THE

FURTHER GRANT OF AWARDS UNDER

THE 2021 RSU SCHEME AND THE
2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER

THE POST IPO SHARE OPTION SCHEME

 

Reference is made to the announcement
of Ascentage Pharma Group International (the “Company”) dated June 29, 2026 in connection with the further grant of
RSUs under the 2021 RSU Scheme and the 2022 RSU Scheme, as well as the further grant of Options under the Post IPO Share Option Scheme
(the “Announcement”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings
as those defined in the Announcement.

 

The Company would like to provide
an update that, for the avoidance of doubt, the date of the annual general meeting of the Company at which the Scheme Mandate Limit pursuant
to which the 2021 Awards, 2022 Awards and Options would be satisfied is May 19, 2025 as opposed to May 20, 2026.

 

Save as disclosed above, all other
information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is an
update to and should be read in conjunction with the Announcement.

 

 By order of the Board

 Ascentage Pharma Group International
Dr. Yang Dajun

 
 Chairman and Executive Director

 

 

Suzhou, the PRC, July 13, 2026

 

As at the date of this announcement,
the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote
1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note 2,
Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

 

Notes:

 

1.Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission
and Nasdaq corporate governance requirements.

 

2.Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.